(Adds indicated share prices, detail)
Oct 29 (Reuters) - German healthcare group Fresenius slightly exceeded third-quarter revenue forecasts on Tuesday, citing strong performance of its infusion drugs unit in emerging markets and growth in home treatment at its separately-listed dialysis business.
The group said both its Fresenius Medical Care dialysis unit and drugmaker Kabi delivered strong organic growth despite increased competition in the United States.
The group confirmed its full-year guidance after third-quarter revenues rose by 8% to 8.9 billion euros in the third quarter, compared to 8.7 billion euros in a company-compiled consensus.
Shares in Fresenius were up 4% in pre-market trade, while Fresenius Medical Care shares were up 3.2%.
"Our businesses developed solidly in the third quarter, keeping Fresenius on track to deliver the results that we promised earlier this year," Chief Executive Stephan Sturm said in a statement.
Fresenius Medical Care, reported a 9% rise in its third-quarter revenue, citing record growth in home dialysis in North America.
FMC's earnings came in slightly above expectations despite an adjustment for income from a U.S. programme known as ESCO, established to coordinate the care of dialysis patients.
The "ESCO effect" in the third quarter had a negative impact of 46 million euros on FMC's revenue as well as earnings before interest and tax (EBIT), and 33 million euros on net income, the company said.
In July, the company lowered the range in which it expected to receive the ESCO lump-sum reimbursement by 41 million euros in the second quarter, causing shares to plummet.
Third-quarter sales of the world's largest provider of dialysis treatments came in at 4.4 billion euros ($4.9 billion), a touch above analysts' average forecast of 4.3 billion euros in a company-compiled consensus.
Fresenius Medical Care confirmed its 2019 guidance of adjusted revenue growth between 3% and 7% in constant currency, and adjusted net income change to be in the range of -2% to 2%.
For 2020, the company expects adjusted revenue as well as adjusted net income to grow at a mid to high single digit rate. (Reporting by Zuzanna Szymanska in Gdansk Editing by Tomasz Janowski)